Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ).
Shanghai Pharmaceuticals Holding Co., Ltd. announced a change in shareholder interest following an equity transfer agreement between Shanghai Shangshi (Group) Co., Ltd. and Shanghai International Investment Limited. This transfer, valued at RMB1,484.7498 million, results in Shanghai Industrial Investment (Holdings) Company Limited maintaining control over a significant portion of the company’s shares, totaling 38.465% of the company’s total share capital. This strategic move consolidates SIIC’s control, potentially impacting the company’s market operations and shareholder dynamics.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in China, operating within the pharmaceutical industry. The company is involved in the production and distribution of pharmaceutical products, focusing on both domestic and international markets.
YTD Price Performance: 0.30%
Average Trading Volume: 4,056,881
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$76.51B
For detailed information about 2607 stock, go to TipRanks’ Stock Analysis page.